Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
FAM13B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM13B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM13B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM13A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM13A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM13A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM9C Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM9C Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM9C, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM9B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM9B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM9B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM9A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM9A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM9A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM8A1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM8A1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM8A1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM3D Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM3D Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM3D, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM3C Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM3C Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM3C, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM3B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM3B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM3B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAM3A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAM3A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAM3A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAIM2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAIM2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAIM2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FAIM Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FAIM Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
4 August 2026
A visual target evaluation report for FAIM, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →